CvergenX, NCI Partner on Radiation Therapy Prediction Assay | GenomeWeb

NEW YORK (GenomeWeb News) – With the help of the National Cancer Institute, CvergenX is developing a radiosensitivity test for use in determining how patients respond to radiation therapy, the company said late Tuesday.

NCI has chosen CvergenX's technology called InterveneXRT for further development and validation in a commercial collaboration in order to advance the assay for use in clinical trials and potentially approval by the US Food and Drug Administration. CvergenX is developing the technology in conjunction with NCI's Clinical Assay Development Program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.